Comparison between GnRH agonist and antagonist protocols for severe endometriosis in assisted reproductive cycles

Abstract

Purpose

Endometriosis may influence different aspects of reproductive physiology including folliculogenesis, ovulation, embryo quality, and fertilization. Recent data demonstrate that patients with endometriosis-associated infertility undergoing in vitro fertilization (IVF) have a reduction of pregnancy rates compared to women with other indications for IVF. The aim of the study is to evaluate the outcomes of IVF after controlled ovarian hyperstimulation (COH) with GnRH antagonist (GnRH-ant) or GnRH agonist (GnRH-a) in severe endometriosis patients.

Methods

A total of 101 patients with severe endometriosis undergoing IVF cycles were retrospectively enrolled into two groups in relation to hypothalamic inhibition before COH, obtained respectively with leuprorelin and cetrorelix. We evaluated characteristics of COH and clinical outcomes (overall pregnancy rate, implantation rate, spontaneous miscarriages, ectopic pregnancies, and clinical pregnancy rates).

Results

The group treated with GnRH-ant presented a similar number of MII oocytes and good quality embryos while using a lower amount of gonadotropins. Outcomes of COH with both GnRH-ant and GnRH-a were similar in patients with stage III-IV endometriosis. The number of retrieved oocytes, the number of obtained embryos, the implantation rates, and the clinical pregnancy rates were similar with GnRH-ant and GnRH-a protocols.

Conclusions

Considering the pregnancy outcomes, COH with both GnRH-ant and GnRH-a protocols do not present statistical differences in patients with severe endometriosis, but the GnRH-ant protocol could be more convenient in term of gonadotropins amount and patient discomfort.

Keywords

Controlled ovarian hyperstimulation Endometriosis GnRH analogs In vitro fertilization

Get full access to this article

View all access options for this article.

References

Practice Committee of the American Society for Reproductive Medicine.

Endometriosis and infertility.

Fertil Steril 2004; 82: S40–5.

Ferrero

, Gillott

D.J.

, Remorgida

, Anserini

, Ragni

, Grudzinskas

J.G.

. Peritoneal fluid proteome in women with different ASRM stages of endometriosis. Gynecol Endocrinol 2008; 24: 433–41.

D'Hooghe

T.M.

, Debrock

, Hill

J.A.

, Meuleman

. Endometriosis and subfertility: is the relationship resolved? Semin Reprod Med 2003; 21: 243–54.

Garcia-Velasco

J.A.

, Somigliana

. Management of endometriomas in women requiring IVF: to touch or not to touch. Hum Reprod 2009; 24: 496–501.

Al-Fadhli

, Kelly

S.M.

, Tulandi

, Tanr

S.L.

. Effects of different stages of endometriosis on the outcome of in vitro fertilization. J Obstet Gynaecol Can 2006; 28: 888–91.

Chillik

C.F.

, Acosta

A.A.

, Garcia

J.E.

The role of in vitro fertilization in infertile patients with endometriosis.

Fertil Steril 1985; 44: 56–61.

Geber

, Paraschos

, Atkinson

, Margara

, Winston

R.M.

. Results of IVF in patients with endometriosis: the severity of the disease does not affect outcome, or the incidence of miscarriage. Hum Reprod 1995; 10: 1507–11.

Olivennes

, Feldberg

, Liu

H.C.

, Cohen

, Moy

, Rosenwaks

. Endometriosis: a stage by stage analysis—the role of in vitro fertilization. Fertil Steril 1995; 64: 392–8.

Barnhart

, Dunsmoor-Su

, Coutifaris

. Effect of endometriosis on in vitro fertilization. Fertil Steril 2002; 77: 1148–55.

10.

Kennedy

, Bergqvist

, Chapron

, D'Hooghe

, Dunselman

, Greb

. ESHRE special interest group for endometriosis and endometrium guideline development group. ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod 2005; 20: 2698–704.

11.

Sallam

H.N.

, Garcia-Velasco

J.A.

, Dias

, Arici

. Long-term pituitary down-regulation before in vitro fertilization (IVF) for women with endometriosis. Cochrane Database Syst Rev 2006.

12.

Schenken

R.S.

, Guzick

D.S.

. Revised endometriosis classification: 1996. Fertil Steril 1997; 67: 815–6.

13.

Veeck

L.L.

. Pre-embryo Grading. In: Atlas of human oocyte and early concepts, eds. Vol. 2. Maryland: Williams and Wilkins, 1991: 121.

14.

Practice Committee of the American Society for Reproductive Medicine.

Endometriosis and infertility.

Fertil Steril 2006; 86: S156–60.

15.

Dechaud

, Dechanet

, Brunet

, Reyftmann

, Hamamah

, Hedon

. Endometriosis and in vitro fertilisation: a review. Gynecol Endocrinol 2009; 25: 717–21.

16.

Coccia

M.E.

, Rizzello

, Mariani

, Bulletti

, Palagiano

, Scarselli

. Impact of endometriosis on in vitro fertilization and embryo transfer cycles in young women: a stage-dependent interference. Acta Obstet Gynecol Scand 2011; 90: 1232–8.

17.

Albuquerque

L.E.

, Saconato

, Maciel

M.C.

. Depot versus daily administration of gonadotrophin releasing hormone agonist protocols for pituitary desensitization in assisted reproduction cycles. Cochrane Database Syst Rev. 2005 Jan 25;(1): CD002808.

18.

Al-Inany

, Aboulghar

. GnRH antagonist in assisted reproduction: a Cochrane review. Hum Reprod 2002; 17: 874–85.

19.

Merviel

, Antoine

J.M.

, Mathieu

, Millot

, Mandelbaum

, Uzan

. Luteinizing hormone concentrations after gonadotropin-releasing hormone antagonist administration do not influence pregnancy rates in in vitro fertilization-embryo transfer. Fertil Steril 2004; 82: 119–25.

20.

Ludwig

, Albano

, Olivennes

Plasma and follicular fluid concentrations of LHRH antagonist cetrorelix (Cetrotide) in controlled ovarian stimulation for IVF.

Arch Gynecol Obstet 2002; 266: 12–7.

21.

Pabuccu

, Onalan

, Kaya

. GnRH agonist and antagonist protocols for stage I-II endometriosis and endometrioma in vitro fertilization/intracytoplasmic sperm injection cycles. Fertil Steril 2007; 88: 832–9. Epub 2007 Apr 10.